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Abstract
In aortic stenosis plasma lipoprotein-derived lipids accumulate in aortic valves. Here, we first compared the lipid
compositions of stenotic aortic valves and atherosclerotic plaque cores. Both pathological tissues were found to be enriched
in cholesteryl linoleate, a marker of extracellularly accumulated lipoproteins. In addition, a large proportion of the
phospholipids were found to contain arachidonic acid, the common precursor of a number of proinflammatory lipid
mediators. Next, we isolated and characterized extracellular lipid particles from human stenotic and non-stenotic control
valves, and compared them to plasma lipoproteins from the same subjects. The extracellular valvular lipid particles were
isolated from 15 stenotic and 14 non-stenotic aortic valves. Significantly more apoB-100-containing lipid particles were
found in the stenotic than in the non-stenotic valves. The majority of the lipid particles isolated from the non-stenotic valves
had sizes (2366.2 nm in diameter) similar to those of plasma low density lipoprotein (LDL) (2261.5 nm), while the lipid
particles from stenotic valves were not of uniform size, their sizes ranging from 18 to more than 500 nm. The lipid particles
showed signs of oxidative modifications, and when compared to isolated plasma LDL particles, the lipid particles isolated
from the stenotic valves had a higher sphingomyelin/phosphatidylcholine –ratio, and also higher contents of
lysophosphatidylcholine and unesterified cholesterol. The findings of the present study reveal, for the first time, that in
stenotic human aortic valves, infiltrated plasma lipoproteins have undergone oxidative and lipolytic modifications, and
become fused and aggregated. The generated large lipid particles may contribute to the pathogenesis of human aortic
stenosis.
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Introduction
The non-rheumatic calcific aortic valve disease, or simply,
aortic stenosis (AS), is an active fibrocalcific condition of the aortic
valves, and it develops gradually over decades before becoming
clinically manifested [1]. The development of AS has been
paralleled to the development of atherosclerosis and the two
diseases share several risk factors, among them elevated plasma
low density lipoprotein (LDL) cholesterol and triglyceride levels
[2,3,4]. However, there are significant differences in the develop-
ment of the two diseases and the role of lipid accumulation in AS
has been debated, particularly since plasma lipid-lowering
therapies have been unsuccessful in slowing AS progression [5,6].
The lesions in aortic valves emerge subendothelially on the
aortic side of the valvular leaflets, where the endothelial cells most
likely get damaged as a result of severe shear stress, the
dysfunctional endothelium then providing access for plasma
lipoproteins and leukocytes to the subendothelial fibrosa layer
[7,8]. Importantly, this subendothelial layer contains a proteogly-
can-rich extracellular matrix [9], i.e. a matrix offering a suitable
ground for lipoprotein retention [10,11]. Indeed, in aortic valves,
apoB-100 has been detected already in early stages of the disease
development and its amount increases with the progression of the
disease [12,13].
During progression of the AS, inflammatory cells such as
macrophages, T cells, and mast cells accumulate in the diseased
valves [14,15], where the cells can secrete various enzymes and
agents capable of modifying the retained lipoproteins. The
modified lipoproteins can aggregate and fuse [16] and, in fact,
extracellular aggregated and fused lipid particles have been shown
to accumulate in the stenotic aortic valves of hypercholesterolemic
rabbits [17,18]. Interestingly, in this animal model, the first sign of
lipid accumulation in aortic valves is the appearance of
extracellular lipid particles rich in unesterified cholesterol (UC)
[17]. The modified lipoproteins can activate the valvular
inflammatory cells, which, by secreting proinflammatory cyto-
kines, may further promote the progression of AS by accelerating
valvular fibrosis and calcification. Indeed, in stenotic leaflets
valvular cells undergo phenotypic transdifferentiation into bone-
forming cells, a process that is induced by inflammatory cytokines
and oxidized cholesterol [3].
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Based on the above information, we hypothesized that the
infiltrated lipoproteins undergo extracellular modification, thereby
leading to aggregation and fusion of lipoproteins and extracellular
lipid accumulation in diseased human aortic valves. To test this
hypothesis, we isolated and characterized extracellular lipid
particles derived from stenotic aortic valves obtained from patients
undergoing valvular surgery. We found that the particles
contained apoB-100 and were aggregated and fused having sizes
ranging from 18 to 500 nm. When compared to plasma
lipoproteins obtained from the same patients, the particles were
not only larger, but also showed signs of oxidation and had a
decreased phosphatidylcholine/sphingomyelin (PC/SM) –ratio,
an increased content of lysophosphatidylcholine (LPC), and an
increased ratio of unesterified/esterified cholesterol (UC/CE), all
of which suggest that significant modification of the apoB-100-
containing lipoproteins had taken place in the stenotic aortic
valves during disease progression.
Materials and Methods
Ethics statement
The use of human material conforms to the principles outlined
in the Declaration of Helsinki and the study was approved by the
Ethics Committee of Helsinki University Central Hospital and the
National Authority for Medicolegal Affairs. All surgical partici-
pants signed an informed consent document.
Human plasma was obtained from healthy blood donors, who
had signed an informed consent document. The plasma samples
were by-products from the preparation of blood products for
clinical use. The use of plasma samples in lipoprotein isolation was
approved by the Finnish Red Cross Blood Service.
Biological samples
Non-rheumatic stenotic aortic valves were obtained from 23
patients (Table 1) undergoing a valve replacement surgery. The
control valves (Table 2) were obtained from autopsy samples
(n = 3), from patients undergoing a valve replacement surgery due
to aortic insufficiency (n = 6), and from heart transplant recipients
or donors (n = 5). The diagnostic criteria for AS were defined
according to the American College of Cardiology and the
American Heart Association 2008 guidelines [19] and were as
follows: for severe AS the aortic valve area ,1 cm2, the mean
pressure gradient.40 mmHg, and the aortic jet velocity.4.0 m/
s; and for moderate AS the aortic valve area 1–1.5 cm2, the mean
pressure gradient 25–40 mmHg, and the aortic jet velocity 3–
4 m/s. Detailed descriptions of the patients are shown in Tables 1
and 2. Samples of atherosclerotic abdominal aortae were obtained
at autopsy (n = 3).
Plasma lipoproteins
Human blood plasma was obtained from healthy volunteers
(Finnish Red Cross Blood Transfusion Center, Helsinki, Finland),
and from the patients undergoing cardiac valve surgery. Plasma
very low density lipoprotein (VLDL) (d,1.006 g/ml), intermediate
density lipoprotein (IDL) (d=1.006–1.019 g/ml), and LDL
(d=1.019–1.050 g/ml) were isolated by sequential ultracentrifu-
gation in the presence of 3 mmol/l Na2EDTA [20,21]. For this
purpose, EDTA and 100 mg/ml Gentamicin sulfate (Lonza, Basel,
Switzerland) were added to plasma, after which the plasma was
centrifuged at 40 000 rpm (rotor 50.2 Ti, gmax 302 000) at +4uC
for 24 h. The VLDL fraction was collected from the top of the
tube, and the density of the remaining plasma was set to 1.019 g/
ml with KBr. The density-adjusted plasma was then centrifuged at
40 000 rpm for 24 h, after which the IDL fraction was collected
from the top of the tube. Finally, the density of the remaining
plasma was set to 1.050 g/ml with KBr, the density-adjusted
plasma was centrifuged at 40 000 rpm for 24 h, after which the
LDL fraction was collected from the top of the tube. LDL was
recentrifuged at a density of 1.063 g/ml, collected and all the
lipoprotein preparations were dialyzed extensively against 1 mM
EDTA - 150 mM NaCl, pH 7.4. The quantities of the lipoprotein
particles are expressed in terms of their protein concentrations,
which were determined by the method of Lowry et al. [22], with
bovine serum albumin as standard.
Isolation of the extracellular lipid particles
Extracellular lipid particles were isolated from the aortic valves
essentially as described by Li and co-workers [23]. An entire single
leaflet from each valve was used for lipid particle isolation and
characterization. Briefly, each frozen leaflet was homogenized
with mortar and pestle in liquid nitrogen. The homogenate was
suspended in isolation buffer (0.01 M Tris - 0.15 M NaCl, pH 7.4,
containing 0.02 mM butylated hydroxytoluene (BHT), 0.1%
EDTA, 0.01% sodium azide (NaN3), and a protease inhibitor
mix (Roche Complete cat 11873580001, Roche Diagnostics,
Germany) in microcentrifuge tubes (LoBind, Eppendorf, Ger-
many). First, the microcentrifuge tubes were gently shaken for
5 min, after which the tissue material was pelleted by centrifuga-
tion (10 min at 10 000 g, 4uC). The supernatants containing the
extracellular lipid particles were transferred to a new tube; the
pellet was resuspended in fresh isolation buffer, and placed in an
ultrasonic bath in ice water to release the still remaining
extracellular lipid particles. The sonicated isolate was again
centrifuged (30 min at 10 000 g) to sediment the residual tissue
material, and the supernatants were pooled. The final density of
the lipid particle containing supernatant was 1.016 g/ml. For
floating of the lipid particles by ultracentrifugation, the density of
the supernatants was increased to 1.063 g/ml by adding buffer A
(0.1 M Tris, 1.5 M NaCl in D2O; d=1.116 g/ml) after which the
ultracentrifuge tubes were filled with separation buffer, the density
of which was set to 1.063 g/ml by mixing buffer A and buffer B
(0.1 M Tris, 1.5 M NaCl in H20; d=1.006 g/ml). After centri-
fugation in a SW41Ti rotor, (Beckman Coulter, 40 000 rpm,
gmax=288 0006g) for 16 h at 4uC, lipid particles were recovered
in 1 ml of separation buffer from the top of the ultracentrifuge
tubes.
Electron microscopy
Particle sizes were also assessed by negatively stained electron
microscopy [24]. For negative staining electron microscopy, LDL
and the extracellular lipid particle samples (5 ml from the isolated
particles, and 5 ml from the LDL) were dried on carbon-coated
grids, after which 5 ml of 1% potassium phosphotungstate, pH 7.4,
was added and also dried on the grids. The samples were viewed
and photographed in a JEOL 1200EX electron microscope at the
Institute for Biotechnology, Department of Electron Microscopy,
Helsinki, Finland.
Fractionation of the isolated lipid particles
The lipoprotein particles were fractionated using rate zonal
ultracentrifugation as described earlier [25] except that a
discontinuous D2O density gradient was used. The gradients were
created by mixing buffer A and buffer B, as described under the
Methods. The buffers were layered in 9/1663K inch Ultra Clear
centrifuge tubes (Beckman Coulter), coated with free fatty acid -
free bovine serum albumin (Sigma) as follows: 1 ml of the solution
containing the isolated extracellular lipid particles (density set to
1.094 g/ml with buffer A) was applied to the bottom of the tube.
Extracellular Lipid Particles in Aortic Stenosis
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Next, three 3 ml layers of the buffers were added, their respective
densities being 1.079 g/ml, 1.050 g/ml, and 1.030 g/ml. Finally,
2 ml of buffer B (d=1.006 g/ml) was added. The gradients were
centrifuged for 1 hour at 40 000 rpm (rotor SW-41 Ti). The
layered buffer solution was then fractionated into 500 ml aliquots.
Analysis of the isolated lipid particles. The cholesterol
content of the isolated lipid particles was measured using a
fluorometric Amplex Red Cholesterol Assay Kit (Molecular
Probes Europe BV, Leiden, The Netherlands). The apolipoprotein
B-100 (apoB-100) -contents of the fractions were measured using
specific ELISAs (MABTECH, Nacka, Sweden). The sizes of
isolated lipid particles and lipoprotein particles were measured
using dynamic light scattering (Zetasizer Nano, Malvern Instru-
ments, Malvern Works, UK).
Determination of oxidized epitopes in LDL. Extracellular
particles were isolated from 5 stenotic valve leaflets (Table 1,
patients P and Q, and additional leaflets from patients K, L and
M). Total valve leaflet tissue mass was 9360 mg and total protein
concentration of the isolate was 0.3 mg/ml. The extracellular
particles were pooled, and oxidized epitopes in the isolated
particles were detected using antibodies recognizing malondialde-
hyde (MDA) -modified LDL (MDA-LDL) and malondialdehyde
acetaldehyde (MAA) -modified LDL (MAA-LDL) epitopes
[26,27]. Monoclonal antibodies were generated by fusing mouse
splenocytes with P3xAg8.653.1 myeloma cell line using standard
methods, and selected based on their binding to MDA-LDL and
MAA-LDL. Clones HMN-08_34 [26], HME-04_7 [27], and
HME-04_6 [26] were cloned as described previously. Clone
HMC+10_101 was cloned from splenocytes of C57BL/6 mouse
immunized with mouse-MDA-LDL without adjuvant. ApoB
containing particles and oxidized LDL-epitopes were detected by
chemiluminescent immunoassay method. Samples were diluted
5 mg/ml in PBS-0.27 mM EDTA and immobilized on 96-well
plate (50 ml/well) overnight at +4uC. The wells were blocked with
0.5% fish gelatin - 0.27 mM EDTA -PBS for 1 hour at room
temperature. The antibodies were biotinylated and diluted in
0.5% fish gelatin - 0.27 mM EDTA - PBS as follows: HMN-
08_34, 2 mg/ml, HME-04_7, 1 mg/ml, HME-04_6, 2.5 m/ml,
and HMC+10_101, 4 mg/ml. Goat anti-human apoB-48/100
(Meridian Life Sciences, Memphis, Tennessee, USA) 0.1 mg/ml
was used to detect apoB containing particles. Antibody dilutions
(50 ml/well) were added in duplicate wells and incubated for
1 hour at room temperature. Bound antibodies were detected with
alkaline phosphatase labeled NeutrAvidin (Thermo Scientific,
Rockford, Illinois, USA), and LumiPhos 530 substrate (Lumigen
Co, Southfiel, Michigan, USA). NeutrAvidin-ALP was diluted
1:18000 in 0.5% fish gelatin – 1 mM MgCl2- TBS and 50 ml was
added in each well for 1 hour at room temperature. LumiPhos 530
was diluted 1:3 in H2O and 25 ml was added in each well. After
incubation for 90 minutes at room temperature, the luminescence
was detected with Victor 3 multilabel counter. The wells were
washed after each step with automated plate washer and PBS-
Table 1. Clinical characteristics of the patients with aortic valve stenosis.
Subject Sex Age. y BMI Diagnosis Clinical history Statin Smoking
Dys-
lipidemia
Valve leaflet
weight (mg)
A F 67 29 AS Diabetes + 2 + 1892
B F 82 22 AS+AI Hypertension, diabetes 2 2 + 633
C M 73 23 AS Diabetes + + + 605
D F 70 26 AS - 2 2 2 1773
E M 81 24 AS Hypertension, kidney disease 2 2 2 2067
F M 74 N/A AS Hypertension + 2 + 930
G M 58 28 AS Hypertension, diabetes, TIA/stroke + + + 1876
H F 75 30 AS - 2 2 + 1476
I M 80 22 AS Hypertension + + + 1393
J F 61 23 AS - 2 + 2 1520
K F 70 31 AS TIA/stroke + 2 + 659 and 767
L M 53 22 AS - + + + 1950 and 1080
M M 53 27 AS Hypertension + 2 + 1827 and 2367
N M 64 37 AS Diabetes 2 2 + 1668
O F 86 N/A AS - 2 2 N/A 852
P F 72 21 AS Hypertension + 2 + 779
Q M 43 37 AS - + 2 + 4367
R M 37 27 AS+AI Hypertension 2 + + 295
S F 86 22 AS+AI - 2 2 2 2308
T F 75 30 AS - 2 2 2 392
U F 65 28 AS+AI - 2 2 N/A 778
V F 76 33 AS Hypertension, Diabetes + 2 + 1321
X M 63 31 AS Hypertension + + + 1594
AS indicates aortic stenosis; AI, aortic insufficiency; N/A, data not available. Aortic valve leaflets of patients A–O were used for characterization of the size and
composition of the extracellular particles. Extracellular particles isolated from the valve leaflets of patients P and Q, and from additional leaflets of patients K, L and M
were assayed for oxidative modification. Valve leaflets of patients R–X were used for lipid extraction and lipidomic analysis by mass spectrometry.
doi:10.1371/journal.pone.0065810.t001
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0.27 mM EDTA. Results are expressed as relative light units
measured in 100 ms (RLU/100 ms).
Mass spectrometry of aortic valves. For electrospray
ionization-mass spectrometry (ESI-MS), the lipids in the excised
aortic valves (Table 1, patients R-X) and in the extracellular
particles isolated from them, were extracted [28], concentrated
under nitrogen flow, and dissolved in chloroform-methanol (1:2,
v/v). The extractions were carried out twice to carefully remove
any remaining water soluble substances. As control samples, lipid
cores of aortic plaques obtained from abdominal aortae from
autopsied subjects (n = 3), and prepared in the same way were
used. The samples had been spiked with a cocktail of several
quantitative standards (Table 3), and to support ionization and
prevent adduct formation, just prior to the analysis, NH3 was
added to the samples to give a final concentration of 1% (v/v). The
mass spectra were recorded in positive ionization mode by using
Bruker Esquire-LC ion trap ESI-MS equipment (Bruker Dal-
tonics, Bremen, Germany). In order to resolve overlapping peak
patterns and peak areas, and accurately quantify each lipid species,
the data were further analyzed with DataAnalysis 3.4. (Bruker
Daltonics), and LIMSA [29] software.
Thin layer chromatography. Lipids in the different samples
were extracted as described above, and the contents of neutral
lipids and phospholipids were determined using thin layer
chromatography (CAMAG Automatic TLC-sampler III, Mutten,
Switzerland) together with a separate standard compound for each
lipid class. Standard curves were also calculated separately for
each lipid class. The compounds were separated on the silica plate
using as eluent hexane/diethyl ether/acetic acid/water
(260:60:4:1, v/v/v/v) for the neutral lipids and chloroform/
methanol/acetic acid/water (25:15:4:1, v/v/v/v) for the phos-
pholipids. The plates were developed by dipping them shortly in
the development solution (2 M H2PO4, 0.2 M CuSO4) and
charring them on a hot plate until all the standards representing
each major lipid class of the samples became visible. The plates
were subsequently scanned and measured under ultraviolet light
(CAMAG TLC-scanner, Mutten, Switzerland) and the areas were
integrated using CAMAG Software v, 4.06.
Isolation of intracellular lipid droplets from human
monocyte-derived macrophage foam cells. Human mono-
cytes were isolated from buffy coats (obtained from the Finnish
Red Cross Blood Transfusion Center, Helsinki, Finland) and
differentiated into macrophages in the presence of M-CSF as
described in [30]. On day 7 the cells were loaded with acetyl-LDL
(0.05 mg/ml) for 24 h. Acetyl-LDL was prepared by modifying
human LDL by treatment with acetic acid anhydride [31].
Macrophages loaded with acetyl-LDL were washed thrice. The
lipid droplets were isolated by preparing a lysate of the cells by
adding 1 ml cold water to the cells, scraping them off the bottles
Table 2. Clinical characteristics of the patients without aortic valve stenosis, whose aortic valve leaflets were used as controls.
Subject Sex Age. y BMI Diagnosis Clinical history Statin Smoking Dyslipidemia
Valve
leaflet
weight
(mg)
a M 69 25 AI Hypertension. 2 2 2 214
b M 65 30 AI Kidney disease, Lung disease 2 2 2 290
c F 79 27 AI Hypertension, diabetes, kidney
disease
2 2 2 173
d F 62 25 AI Hypertension 2 2 2 135
e M 71 21 AI Hypertension, kidney disease 2 + + 352
f M 55 23 AI Hypertension 2 2 2 186
g M 58 N/A Dilated CMP Kidney disease 2 2 2 248
h F 63 33 Intracerebral hematoma N/A N/A N/A N/A 270
i M 58 N/A CHF TIA/Stroke, Lung disease + + 2 413
j M 42 27 Subarachnoidal
hematoma
N/A N/A N/A N/A 314
k F 58 59 Pulmonary embolism TIA/Stroke N/A N/A N/A 201
l F 64 N/A Dilated CMP - 2 2 2 291
m M 74 26 AMI N/A 2 N/A N/A 436
n F 66 22 Epileptic seizure N/A N/A N/A N/A 347
AI indicates aortic insufficiency; CMP, cardiomyopathy; AMI, acute myocardial infarction; CHF, congestive heart failure; N/A, data not available.
doi:10.1371/journal.pone.0065810.t002
Table 3. Lipid standards used for mass spectrometry.
Lipid class m/z c (pmol/ml)
CE 16:0 642 7.52
SM 12:0 647 0.73
PC 40:2 842 0.29
Cer 12:0 482 0.73
LPC 14:0 468 0.73
TAG 42:0 740 1.45
PE 28:0 636 0.29
PS 28:0 676 0.29
Lipid standards used for mass spectrometric analysis of the atherosclerotic
plaques, excised aortic valves and extracellular lipid particles isolated from
stenotic aortic valves. Each analyzed sample was spiked with the standard
mixture for quantitative measurement and the abundances of each lipid species
were calculated as mole percentages.
doi:10.1371/journal.pone.0065810.t003
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and drawing the cells through a 26G needle several times. The
cytoplasmic cholesteryl ester (CE)-containing lipid droplets were
then isolated by centrifugation (24 000 rpm in a SW 41 Ti rotor at
+4uC for 60 min, after which the floating fat cake, containing the
lipid droplets, was collected from the top of the centrifuge tube [32].
Adipophilin Western blot analysis. The intracellular lipid
droplets and extracellular lipid particles were delipidated [33], and
analyzed for the presence of adipophilin by Western blot analysis
[33,34].
Statistical analysis. The statistical analysis was carried out
with PASW20, using the nonparametric Kruskal-Wallis test, with
the level of significance defined as p,0.05.
Results
Lipids were extracted from 6 stenotic valve leaflets (Table 1,
subjects R-X) and from the cores of 3 atherosclerotic plaques, after
which their lipid compositions were analyzed by ESI-MS.
Representative mass spectra are shown in Figures 1 and 2. In
both cases, the major species of CEs were cholesteryl linoleate
(18:2; m/z 666) and cholesteryl oleate (18:1; m/z 668). Cholesterol
linoleate (18:2) is the major CE in lipoprotein particles, while
cholesteryl oleate (18:1) is found particularly in the intracellular
CE droplets [35]. Based on this information, the 18:1/[18:1+18:2]
ratio has been used as a marker of intracellular vs. extracellular
lipid accumulation [36], the ratio ranging from 0.2 to 0.47 in
extracellular lipids, while being as high as 0.8 in intracellular lipid
droplets. We found that in the whole stenotic aortic valves and in
the atherosclerotic plaque cores, the 18:1/[18:1+18:2] ratios were,
on average 0.19 (60.05; median 0.19) and 0.22 (60.01; median
0.23), respectively, a finding indicating that the accumulated lipids
in both tissues were mainly of extracellular origin. In the healthy
aortic valves, however, the amount of extracellular particles that
could be isolated from a whole valve leaflet was too small to
acquire reliable results of the amount of CEs or fatty acids in the
extracellular lipid particles.
Atherosclerosis and aortic valve stenosis are considered inflam-
matory diseases. Indeed, in both tissues, large amounts of lipid
species containing arachidonic acid (20:4n-6), an important
inflammatory mediator [37], were seen. Thus, PC species that,
according to fatty acid fragments detected, contain arachidonic
acid in their sn2 position, namely 36:4 (m/z 782), 36:5 (m/z 780),
38:4 (m/z 810) and 38:5 (m/z 808), as well as arachidonic acid-
containing LPC species (m/z 544), were abundant in both the
atherosclerotic plaques and in the stenotic aortic valves (Figure 2).
The sum of the above-mentioned PC species was, on average,
22.4% in the stenotic aortic valves and 19.1% in the atheroscle-
rotic plaque cores (Table 4). Similarly, 12% and 6% of the LPC
species in the stenotic aortic valves and in the atherosclerotic
plaque cores, respectively, contained arachidonic acid.
Next, we isolated lipid particles from aortic valves using a
method that has been optimized for isolation of extracellular lipid
particles from tissues [23]. Stenotic valve leaflets (n = 15) were
much thicker and heavier than were non-stenotic leaflets (n = 14),
their weights ranging from 600 mg to 2100 mg and from 130 mg
to 430 mg, respectively. To isolate the lipid particles, crude isolates
of the stenotic and non-stenotic valves were subjected to
ultracentrifugation at a density of 1.063 g/ml, i.e. at a density at
which VLDL, IDL, and LDL particles can be recovered from the
top of the ultracentrifuge tube. After the density ultracentrifuga-
tion step, the isolated extracellular lipid particles were negatively
stained and viewed under electron microscope (Figure 3 A). As the
extracellular lipid particles were found to be heterogeneous in size,
some particles being considerably larger than native LDL, rate
zonal ultracentrifugation was used to further separate the particles
into fractions according to their sizes. Figure 3 shows also
representative flotation profiles of plasma LDL (Panel B), particles
isolated from a non-stenotic control valve (Panel C), and particles
isolated from a stenotic valve (Panel D). The flotation profile of the
lipid particles isolated from the non-stenotic valve resembled that
of plasma LDL, while lipid particles isolated from the stenotic
valves failed to show any single major peak, but rather showed four
smaller peaks, which we termed according to their sizes XL, L, M,
and S. We then pooled the fractions of each peak, and the sizes of
the particles in the four pools of particles in each sample were
measured by dynamic light scattering (Panel E). The particles in
the XL-peak had an average size of 237630 nm (mean 6 SD;
fractions 4–6), those in the L-peak (fractions 9–11) 152625 nm,
those in the M-peak (fractions 15–17) 76614 nm, and those in the
S-peak (fractions 19–21) 2761.9 nm. Representative size distri-
butions of the particles isolated from one whole stenotic valve
leaflet are shown in Figure 4A. The size distribution of the S-
particles was found to resemble that of LDL-particles, while the
size distribution of M-particles resembled more that of VLDL-
particles. Of note, the L and XL-particles were larger than any of
Figure 1. Lipid mass spectrometric analysis of a stenotic aortic
valve and an atherosclerotic plaque. Lipids were extracted from a
stenotic aortic valve leaflet (A) and an atherosclerotic aortic plaque (B)
as described under Methods. The lipid extracts were analysed by ESI-ion
trap mass spectrometer. The main CE species (cholesteryl linoleate (m/z
666) and cholesteryl oleate (m/z 668)) are indicated in the mass spectra.
doi:10.1371/journal.pone.0065810.g001
Extracellular Lipid Particles in Aortic Stenosis
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e65810
the apoB-100 containing particles circulating in the plasma of the
patients, yet they were smaller than the experimentally created
intracellular lipid droplets.
To confirm that the isolated lipid particles were mainly of
extracellular origin, the particles were analyzed by Western blot
for the presence of adipophilin, one of the main membrane
Figure 2. Lipid mass spectrometry analysis of PCs in a human stenotic valve and an atherosclerotic plaque.Mass spectra of LPC (Panels
A and C) and PC (Panels B and D) containing arachidonic acid (20:4n-6) in human stenotic aortic valve (A and B) and human atherosclerotic plaque (C
and D). The LPC species for arachidonic acid (m/z 544) in panels A and C is denoted with a black arrow. In panels B and D, the main species containing
PC are 36:4 (16:0/20:4, m/z 782), 36:5 (16:1/24:4, m/z 780), 38:4 (18:0/20:4, m/z 810), and 38:5 (18:1/20:4, m/z 808) (black arrows). PC-species 36:2 (18:0/
18:2, m/z 786) and 36:1 (18:0/18:1, m/z 788) (open arrows) are shown as an abundancy reference.
doi:10.1371/journal.pone.0065810.g002
Extracellular Lipid Particles in Aortic Stenosis
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e65810
proteins of intracellular lipid droplets [38]. Intracellular lipid
droplets isolated from acetyl-LDL-loaded cultured human mono-
cyte-derived macrophages were used as a source of intracellular
CE droplets. Such droplets contained abundantly adipophilin,
whereas only trace amounts of adipophilin were detected in the
lipid particles isolated from stenotic valves derived from 6 patients
(Figure 4B). Importantly, the intracellular lipid droplets isolated
from acetyl-LDL-loaded macrophages were much larger that the
lipid particles isolated from the aortic valves: the intracellular
particles had an average size of 560633 nm (Figure 4A), and they
floated in fractions 1–3 of the rate zonal ultracentrifuge tubes.
These findings strongly suggest that the majority of the lipids,
which had accumulated in the aortic valves, were of extracellular,
rather than of intracellular origin.
To test whether the extracellular lipid particles were oxidatively
modified, we examined the particles in chemiluminescent immu-
noassay using antibodies selected against MDA- or MAA-LDL
(Figure 5). The binding of the antibodies to MDA- and MAA-
modified LDL, as well as to copper oxidized and native LDL is
shown in Figure 5A. Antibody clones HMN-08_34 and HME-
04_7 recognized both MDA- and MAA-modified LDL, and they
bound also to copper-oxidized LDL, but to a lesser extent. The
clones HMC+10_101 and HME-04_6 bound mostly to MAA-
modified LDL. None of the antibodies bound to native LDL. The
binding of anti-human apoB antibody to MAA-LDL, MDA-LDL,
copper-oxidized LDL and native is shown in Figure 5B. The
extracellular lipid particles contained oxidized epitopes that were
recognized by all tested MDA- and MAA-LDL binding antibodies
(Figure 5C). The extracellular lipid particles were also positive for
apoB, the protein component of VLDL, IDL and LDL-particles,
thus revealing their origin as the apoB-100-containing plasma
lipoproteins, i.e. any of the VLDL-IDL-LDL cascade.
The total amounts of cholesterol and apoB-100 in the XL-, L-,
M-, and S-particles isolated from the whole leaflets were next
analyzed (Figures 6A and B). In each particle class, the amount of
cholesterol was much higher in the particles isolated from the
stenotic valves than in those isolated from the non-stenotic valves.
In stenotic valves, similar amounts of cholesterol were found in the
L-, M-, and S- particles, while in the non-stenotic valves, about
half of the cholesterol was in S-particles, and only minor amounts
were found in the larger particles. ApoB-100 was present almost
exclusively in M- and S- particles isolated from the stenotic valves
and in S-particles isolated from the non-stenotic valves, i.e. in those
resembling plasma lipoproteins in their size. The amounts of
cholesterol and apoB-100 were also expressed per mg wet weight
leaflet tissue (Figures 6C and D). Even after the valve leaflet weight
was taken into account, the amounts of cholesterol were found to
be higher in particles isolated from stenotic valves than in those
isolated from non-stenotic valves, the difference being statistically
significant in L- and M-particle classes. In the S- and M-particles
isolated from stenotic valves, the apoB-100 amounts were higher
than in those isolated from non-stenotic valves, even when the
valve leaflet weight was taken into account. The XL- and L-
particles contained very little apoB-100 in both stenotic and non-
stenotic groups.
The ratio of apoB-100 to cholesterol (Figure 6E) showed great
variation among donors. In the non-stenotic valves, the propor-
tions of cholesterol and apoB-100 were similar in all particle
classes. In the stenotic valves, however, the proportion of apoB-
100 was much higher in the S-particles than in the other particle
Table 4. PC and LPC species extracted from atherosclerotic plaques and excised aortic valves.
Valve Plaque
Lipid species Principal acyl chains m/z Average mol % Average mol %
PC32:0 16:0/16:0 734 3.360.5 3.860.1
PC34:0 16:0/18:0 762 4.563.3 2.860.2
PC34:1 16:0/18:1 760 1561.3 1860.9
PC34:2 16:0/18:2 758 1363.4 1160.1
PC36:1 18:0/18:1 788 6.560.5 6.360.4
PC36:2 18:0/18:2, 18:1/18:1 786 1261.9 1260.7
PC36:3 18:1/18:2 784 6.260.7 6.060.7
PC36:4 16:0/20:4 782 8.6±1.2 7.0±0.5
PC36:5 16:1/20:4, 16:0/20:5 780 3.1±0.6 1.8±0.4
PC38:1 20:0/18:1 816 3.160.8 2.360.3
PC38:2 18:0/20:2, 20:0/18:2 814 6.761.7 7.860.5
PC38:3 18:0/20:3 812 4.960.8 6.460.1
PC38:4 18:0/20:4 810 6.4±6.3 6.2±0.1
PC38:5 18:1/20:4 808 4.3±4.3 4.1±0.2
PC38:6 16:0/22:6 806 3.760.9 5.360.5
LPC16:0 16:0 496 46615 4160.6
LPC18:0 18:0 524 30612 3264.9
LPC18:1 18:1 522 1267.1 1663.6
LPC18:2 18:2 520 1268.7 5.163.4
LPC20:4 20:4 544 12±4.9 6.1±0.9
Extracted lipid samples were spiked with the lipid standards (Table 3), and analyzed with a mass spectrometer as described in Materials and Methods. The average
abundances were expressed as mole percentages 6 standard deviation. Arachidonic acid contained phospholipids are emphasized with a bolded typeface.
doi:10.1371/journal.pone.0065810.t004
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classes. In all particle classes from either the stenotic or non-
stenotic valves, the ratio of apoB-100 to total cholesterol was lower
than in the apoB-100 containing plasma lipoproteins, in which it
is, on average, 0.3 in VLDL and 0.5 in LDL [39].
The lipid compositions of the S-, M-, L- and XL-particles from
stenotic aortic valves of seven patients was analyzed by TLC, and
are shown individually as mass percentages (patients A to G in
Figure 7A). For comparison, the lipid compositions of LDL, IDL,
and VLDL are also shown (Figure 7B). The proportions of the
lipids in the S-, M-, L- and XL- particles varied considerably
among the patients. In general, the lipid profiles of the particles in
the four particle classes isolated from a single donor tended to
resemble each other more than the lipid profiles in a single particle
class isolated from different donors. Interestingly, the lipid profiles
of the particles of patient C differed from each other, the M-
particles being extremely rich in phospholipids and the S- and L-
particles being enriched in UC. In general, when compared to
plasma lipoproteins, the ratio of PC to SM was reduced in lipid
particles isolated from the stenotic valves. Also, the proportion of
UC was much higher in the lipid particles than in native plasma
Figure 3 .Electron micrographs and rate zonal ultracentrifuga-
tion of extracellular lipid particles. The extracellular lipid particles
and native LDL were negatively stained and photographed under
electron microscope as described in the Methods (A). Native LDL (B),
lipid particles from a non-stenotic valve (C), and lipid particles from a
stenotic valve (D) were subjected to rate zonal ultracentrifugation as
described under Methods. Fractions (500 ml) were collected and their
cholesterol concentrations were determined. The fractions in each
sample were pooled into four groups based on the floating pattern of
the extracellular lipid particles of the stenotic valves (D). The particle
sizes in each pool were determined using dynamic light scattering and
the average sizes of each particle class are shown in Panel E.
doi:10.1371/journal.pone.0065810.g003
Figure 4. Comparison of extracellular lipid particles to
intracellular lipid droplets. Intracellular lipid droplets were isolated
from acetyl-LDL loaded macrophages as described in the Methods. Rate
zonal ultracentrifugation of the intracellular lipid droplets was carried
out, as described in the Methods. The size distributions of the
intracellular particles and the extracellular lipid particle classes were
measured with dynamic light scattering, extracellular particle classes
(solid lines), intacellular lipid droplets (dashed line) (Panel A). The
isolated lipid droplets, and extracellular lipid particles isolated from the
stenotic aortic valves were analyzed by Western blot for adipophilin
(Panel B) as described in Methods. Lanes 1–6: extracellular lipid particles
from 6 patients; lane 7: intracellular lipid droplets from cultured
monocyte-derived macrophages.
doi:10.1371/journal.pone.0065810.g004
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lipoproteins, being 20–80% and 15–30% of the total cholesterol
content, respectively.
Discussion
In the present study, we have isolated and characterized
extracellular lipid particles from severely stenotic and from non-
stenotic human aortic valves, and we found that their average sizes
ranged from 18 to 270 nm, the largest particles having diameters
of about 500 nm. Earlier, the morphology of extracellular lipid
droplets in the aortic valves of hypercholesterolemic rabbits has
been characterized by aid of electron microscopy [18]. In
remarkable consistency with the present results, the authors found
that prolonged lipid feeding of rabbits was associated with the
appearance of enlarged extracellular lipid particles in the aortic
valves, the sizes of the particles ranging from 23 to 220 nm. In the
present study, the extracellular lipid particles could be divided into
Figure 5. Oxidized epitopes in the extracellular lipid particles. Binding of monoclonal antibodies (clones HMN-08_34, HME-04_7, HMC+10-
101 and HME-04_6) to MDA-LDL, MAA-LDL, copper-oxidized LDL (CuOx-LDL) and native LDL (A). Binding of anti-apoB antibody to the modified LDL-
particles and native LDL (B). Binding of antibodies to lipid particles isolated from the stenotic aortic valves (C,D). Results are expressed as relative light
units measured in 100 ms (RLU/100 ms).
doi:10.1371/journal.pone.0065810.g005
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four groups according to their flotation characteristics, which
corresponded to their sizes. Thus, in rate zonal ultracentrifugation,
four flotation maxima were observed (see Figure 4), and,
accordingly, the particles were classified to S-, M-, L-, and XL-
particles. The S- and M-particles were found to resemble LDL and
VLDL in size, while the L- and XL- particles were larger than any
of the apoB-100 -containing plasma lipoproteins, suggesting that
they are formed from plasma lipoproteins by aggregation and/or
fusion.
The accumulation of extracellular lipid particles in AS
resembles accumulation of extracellular lipid particles in the
arterial intima during atherogenesis, the morphology of which has
been characterized in detail by Guyton and co-workers [36]. In
atherosclerosis, the cause of lipid accumulation is considered to be
the binding and entrapment of plasma lipoproteins by the
components of the arterial extracellular matrix, particularly
proteoglycans [40,41,42,43,44,45]. The accumulation of apoB-
100 –containing lipoproteins has also been shown in human
Figure 6. Total cholesterol and apoB-100 in extracellular particles isolated from stenotic and non-stenotic valves. Total cholesterol (A)
and apoB-100 (B) in each particle class both in the stenotic and in the non-stenotic valves were measured as described in Methods. The amounts of
cholesterol and apoB-100 were also calculated in proportion to the valve leaflet weight (C, D). Panel E shows the calculated relation of apoB-100 to
total cholesterol in each particle class. Outliers are shown as black circles (stenotic valves) and as open triangles (non-stenotic valves). Control vs.
stenotic *p,0.05, **p,0.005.
doi:10.1371/journal.pone.0065810.g006
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stenotic aortic valves [12,13], where they have been found to co-
localize with biglycan and decorin [46]. Once the lipoproteins are
retained by the proteoglycans in the aortic valves, they can
become modified by proteases, lipases, and oxidative agents
present in the extracellular fluid. Such modifications can lead to
aggregation and fusion of the modified lipoproteins and enhance
their binding to the extracellular matrix [47,48,49,50,51,52,53].
Interestingly, the extracellular lipid particles isolated from stenotic
aortic valves in this study resemble such in vitro aggregated and
fused lipoprotein particles both in size and in composition. Thus,
when compared to plasma lipoproteins, the lipid particles had a
decreased PC/SM-ratio, and particles from several donors also
contained significant amounts of LPC. The extracellular lipid
particles from most of the donors contained also very high
amounts of UC. This finding is in accordance with animal studies,
in which high amounts of UC were detected in the extracellular
lipid particles in the aortic and atrio-ventricular valves of
hypercholesterolemic rabbits [18,54,55].
The decreased PC/SM ratio and increased amount of LPC in
the particles have likely resulted from modification of the particles
by oxidation or by phospholipase A2 (PLA2), and a likely source of
UC in these particles is hydrolysis of their CEs by cholesteryl
esterase [56]. Indeed, the isolated lipid particles showed signs of
oxidation, and oxidized LDL has been shown in stenotic aortic
valves in the areas with inflammatory cell infiltration [57]. Since
oxidized lipoproteins are readily taken up by macrophage
scavenger receptors [58], the presence of oxidized particles in
the valvular extracellular space reflects insufficient clearance of the
particles by macrophages and valvular myofibroblasts. Interest-
ingly, the amount of oxidized LDL in valves is associated with the
amount of small dense LDL in circulation, i.e. with the oxidation-
susceptible subfraction of LDL in the blood plasma [57]. Small
dense LDL has been suggested to be the result of phospholipid
hydrolysis on LDL particles [59] and, in fact, the plasma levels of
lipoprotein-associated PLA2 (Lp-PLA2) and small dense LDL
correlate [60]. Importantly, Lp-PLA2 is elevated in patients with
severe aortic valve stenosis, and the aortic valve area correlates
inversely with plasma levels of Lp-PLA2 [61]. Another phospho-
lipase that may hydrolyze LDL phospholipids in the aortic valve is
secreted PLA2 type IIA. This enzyme is present in stenotic aortic
valves [62], can hydrolyze LDL particles [63] and induce their
fusion [25]. UC can be generated by the action of lysosomal acid
lipase, an enzyme, which has been shown to be secreted by
activated macrophages [64], which are abundantly present in
stenotic aortic valves [65].
The presence of oxidized LDL has been shown to be associated
with the degree of valvular inflammation and tissue remodelling
[2,57]. Indeed, oxidized lipoproteins, as well as many of the
products of lipoprotein modifications, such as LPC and fatty acids,
are strong proinflammatory factors [66,67,68]. Arachidonic acid is
an important mediator of inflammation [37], and, as shown in this
study, arachidonic acid-containing lipid species, such as LPC and
PCs are abundant in stenotic aortic valves. Another interesting
bioactive molecule present in the extracellular particles is UC,
which, once crystallized, may trigger a strong inflammatory
response in macrophages [30,69]. The accumulated lipid particles
rich in such proinflammatory molecules can activate neighboring
macrophages, and so act as a nidus for further lipid accumulation
with an ensuing increase in the lipolysis-induced inflammatory
burden in aortic valves. Thus, once lipoprotein particles are
retained in an aortic valve, a self-perpetuating feedback loop may
ensue, in which the proinflammatory lipid species generated can
act as activators of the valvular cells.
The modified lipoproteins may also contribute to valvular
calcification: LPC has been shown to trigger smooth muscle cells
to induce calcification in lipid-rich environment [70]. The idea of
lipid-induced calcification of the aortic valve is supported by the
hypercholesterolemic mouse model of Miller and co-workers [71],
in which hyperlipidemia resulted in elevated superoxide levels,
deposition of lipids and calcium, and expression of pro-osteogenic
proteins in the aortic valve. Interestingly, these adverse valvular
changes, including calcification, were reversed by normalization of
blood cholesterol levels.
Unfortunately, the proposal of lipid accumulation being a
significant component in the development and progression of AS,
as so nicely demonstrated in animal models and retrospective
studies [68], has not gained support from prospective clinical data.
Thus, the presumption that plasma lipid-lowering therapy is of
significant therapeutic value in the prevention and treatment of AS
Figure 7. Lipid analysis of extracellular lipid particles. Lipid
contents of the extracellular particles isolated from seven patients
(patients A to G) were determined by TLC as described in Methods. The
lipid contents of each particle class are shown as mass percentages of
total lipid (A). As a comparison, the lipid contents of plasma LDL, IDL
and VLDL were also determined and are shown here as mass
percentages of total lipid (B).
doi:10.1371/journal.pone.0065810.g007
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[72,73] has suffered severely, as the results of clinical studies
involving plasma lipid-lowering therapy have been uniformly
unsuccessful in slowing AS progression [5,6]. The results of the
present study involving severely stenotic aortic valves indicate that
plasma lipoprotein particles have accumulated and become
extensively modified in the extracellular space of the diseased
valves. Based on this finding, we propose that the type and extent
of lipoprotein modification in the valves, rather than high levels of
circulating plasma lipoproteins per se, are responsible for the
initiation and/or progression of AS. Since in the diseased aortic
valves, denudation of the endothelial cell layer can be observed,
the endothelial barrier function mechanism may be lost, so
allowing free access of LDL particles to the subendothelial
extracellular matrix, irrespective of their concentrations in the
plasma [74]. An important corollary of this proposition is that,
even during statin treatment, the plasma levels of apoB-containing
lipoproteins are high enough to allow lipid accumulation to
proceed. Therefore, as the stenosis develops slowly in the course of
many years, even low infiltration rates of the particles appear to be
sufficient to allow a continuous particle supply for the local
modifying processes. Thus, in addition to plasma lipid lowering
strategies, we should also aim at achieving resolution of the
ongoing inflammatory activation in the diseased valves. Since
some of the promising novel anti-inflammatory mediators are
derivatives of the polyunsaturated fatty acids, including arachi-
donic acid [75], we face a difficult, but hopefully an ultimately
rewarding challenge of resolving the lipid-dependent proinflam-
matory state in the valves and switching it into a lipid-dependent
anti-inflammatory state.
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